Corticosteroid Therapy in Feline Inflammatory Bowel Disease: Dosing and Monitoring

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Prednisolone is the systemic corticosteroid of choice for feline IBD due to inefficient hepatic conversion of prednisone in cats; budesonide is an alternative for refractory or steroid-intolerant cats, though systemic absorption is still a consideration.
• Initial corticosteroid dosing should be at an immunosuppressive range to achieve clinical control, followed by a gradual taper to the lowest effective maintenance dose, guided by resolution of clinical signs rather than solely histologic inflammation.
• Monitoring for therapeutic response and adverse effects is critical, including regular assessment of body weight, muscle condition, glucose levels, and surveillance for infection, with recheck examinations every 2 to 4 weeks during induction.
• Ultrasonographic assessment of adrenal gland height is unreliable for detecting iatrogenic adrenal atrophy in cats; ACTH stimulation testing is the appropriate method if adrenal axis assessment is required.
• Failure to respond to corticosteroids necessitates re-evaluation of the diagnosis before escalating the dose, considering adjunct therapies like thiopurines or chlorambucil, or ruling out conditions such as alimentary lymphoma.
• Corticosteroid-induced complications in cats include diabetes mellitus, skin fragility, and exacerbation of latent infections, with cats being more prone to diabetes and less to classic Cushing's syndrome compared to dogs.

Corticosteroids remain the principal medical intervention for feline inflammatory bowel disease (IBD) when dietary modification alone fails to control clinical signs. This article provides a practical framework for drug selection, initial dosing, tapering protocols, and adverse effect monitoring in cats with IBD. It is written for practicing veterinarians who require a structured approach to a therapy that demands careful individualization.

The clinical question addressed is straightforward: which corticosteroid should be chosen for a given cat, at what starting point, and how should response and toxicity be tracked over time? The answer depends on disease severity, concurrent conditions, and the cat's tolerance of both the drug and the monitoring process. The evidence base for feline IBD therapy is limited, and much of the dosing guidance derives from clinical experience and extrapolation from other species. Where the literature is thin, this article identifies the uncertainty explicitly.

At a Glance

Pathophysiology of Feline IBD and the Rationale for Corticosteroids

Feline IBD is a chronic inflammatory disorder of the gastrointestinal tract characterized by infiltration of the lamina propria with lymphocytes and plasma cells, with variable neutrophilic or eosinophilic components. The inciting cause is incompletely understood, but current models implicate an aberrant mucosal immune response to commensal microbiota or dietary antigens in a genetically susceptible host. This immune dysregulation results in a cycle of epithelial injury, increased mucosal permeability, and further antigen exposure.

Corticosteroids interrupt this cycle through multiple mechanisms. They diffuse across cell membranes and bind cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. The net effect is suppression of proinflammatory cytokine production, reduced leukocyte chemotaxis and activation, decreased vascular permeability, and inhibition of phospholipase A2 activity, which reduces prostaglandin and leukotriene synthesis. These actions produce rapid clinical improvement in most cats, but they do not address the underlying immune dysregulation, which explains the high relapse rate after discontinuation.

The therapeutic goal in feline IBD is not cure but sustained remission with the lowest possible drug exposure. This distinction matters because corticosteroids carry dose-dependent adverse effects, and the feline response to chronic glucocorticoid exposure differs from that of dogs in several clinically relevant ways. Cats are relatively resistant to the classic iatrogenic Cushing's syndrome seen in dogs, but they are more prone to corticosteroid-induced diabetes mellitus, skin fragility, and congestive heart failure in susceptible individuals.

Drug Selection: Prednisolone Versus Alternatives

Prednisolone is the systemic corticosteroid of choice in cats. The liver converts prednisone to the active metabolite prednisolone via 11-beta-hydroxysteroid dehydrogenase, and feline hepatic capacity for this conversion is less efficient than in dogs. Using prednisolone directly avoids reliance on this enzymatic step and provides more predictable bioavailability. Commercial prednisolone formulations are widely available, and the drug is inexpensive and well tolerated by most cats.

The choice between prednisolone and budesonide depends on disease severity and the cat's risk profile. Budesonide is a nonhalogenated corticosteroid with high first-pass hepatic metabolism, which theoretically limits systemic exposure while delivering high local concentrations to the intestinal mucosa. This property makes it attractive for cats with mild to moderate IBD, particularly those with concurrent conditions such as diabetes mellitus or cardiomyopathy that increase the risk of systemic glucocorticoid complications. However, the assumption of negligible systemic absorption has been challenged. Studies in humans and dogs demonstrate measurable systemic effects, including adrenal suppression, and the same is presumed in cats. Budesonide should therefore be treated as a systemic corticosteroid with a favorable therapeutic index, not as a truly topical agent.

Prednisone is occasionally used when prednisolone is unavailable or cost-prohibitive. It is not the preferred agent, and cats receiving prednisone should be monitored for inadequate response before assuming the diagnosis is wrong or the dose is insufficient.

Dosing Principles and Induction Protocols

Dosing for feline IBD follows a staged approach: induction at a higher dose to gain control, followed by a gradual taper to the lowest dose that maintains remission. The induction dose is typically in the immunosuppressive range, and the taper proceeds over weeks to months. Current formulary references and product labels must be consulted for specific milligram per kilogram recommendations, as published ranges vary and individual patient factors alter requirements.

The taper schedule should be guided by clinical response instead of a fixed calendar. Cats that respond promptly may tolerate a more rapid taper, while those with slow improvement require longer intervals at each dose step. The goal is to reduce the dose by approximately 25% every 2 to 4 weeks, provided clinical signs remain controlled. Relapse during the taper indicates that the previous dose was the minimum effective dose, and the cat should be returned to that level before attempting a slower reduction.

A critical caveat applies to the definition of response. Clinical improvement does not guarantee resolution of mucosal inflammation. A retrospective study of cats with lower airway disease found that seven of ten cats had persistent inflammatory cytology on bronchoalveolar lavage despite complete resolution of clinical signs during high-dose oral corticosteroid therapy. The authors concluded that tapering based solely on clinical signs should be re-evaluated. The same principle likely applies to gastrointestinal disease: endoscopic or histologic assessment during remission may reveal ongoing inflammation that predicts early relapse. This is not to mandate repeat endoscopy in every cat, but it argues for a conservative taper and a low threshold for re-evaluation in cats that relapse quickly.

Monitoring for Therapeutic Response

Objective monitoring of response in feline IBD relies on owner-reported signs, physical examination, and serial body weight. Vomiting frequency, defecation quality, appetite, and activity level should be documented at each visit. A standardized clinical scoring system, such as the feline IBD activity index, can improve consistency, though no single system has been universally adopted.

Body weight is the most reliable objective metric. Cats that maintain or gain weight during induction are generally responding, while continued weight loss despite adequate corticosteroid dosing warrants re-evaluation of the diagnosis. This re-evaluation should include repeat abdominal ultrasonography, measurement of serum cobalamin and folate, and consideration of endoscopy with biopsy. Lymphoma can mimic IBD clinically and histologically, and the distinction sometimes requires immunohistochemistry or clonality testing.

Behavioral changes may also signal inadequate control. Cats with inflammatory gastrointestinal disease exhibit more care-soliciting and anxious behaviors than healthy cats, including compulsive grooming and fear of novelty, and these behaviors are more pronounced in cats receiving corticosteroids. Owners should be asked about grooming habits, hiding behavior, and social interactions, as these may improve with effective therapy and worsen during relapse.

Monitoring for Adverse Effects

Cats tolerate corticosteroids better than dogs, but adverse effects still occur and require active surveillance. The most clinically significant complications are diabetes mellitus, skin fragility, and exacerbation of latent infections. Urinary tract infections are common and often subclinical, routine urinalysis and culture are recommended in cats on prolonged therapy, particularly those with concurrent diabetes.

Body weight and muscle condition should be assessed at every visit. Corticosteroid-induced muscle wasting can occur without overt weight loss, and the epaxial muscles and hindlimb musculature should be palpated specifically. Skin fragility manifests as thin, easily torn skin, often first noticed during grooming or routine handling. If skin fragility develops, the corticosteroid dose should be reduced or the drug discontinued, as this complication can be life-threatening.

Adrenal suppression is an expected consequence of prolonged corticosteroid therapy, and the adrenal axis may require weeks to months to recover after discontinuation. Ultrasonographic assessment of adrenal gland height is not a reliable method for detecting iatrogenic adrenal atrophy in cats. A study of 308 cats found that only those receiving anti-inflammatory doses for more than one month showed a measurable decrease in adrenal height, and no useful threshold distinguished treated from untreated cats. If adrenal function must be assessed, an ACTH stimulation test is the appropriate diagnostic tool, though it should be reserved for cats with clinical signs of hypoadrenocorticism or those undergoing surgery or other stressors during the taper period.

When to Escalate or Reconsider

Failure to respond to an adequate course of corticosteroids should prompt a diagnostic re-evaluation instead of an automatic dose increase. The differential diagnosis includes dietary noncompliance, concurrent disease such as pancreatitis or cholangitis, misdiagnosis of lymphoma, and the development of corticosteroid resistance. Repeat imaging and endoscopy with biopsy are indicated in cats that fail induction therapy, as the cost of continued ineffective treatment includes both disease progression and cumulative drug toxicity.

Adjunctive therapies, including thiopurines, chlorambucil, or dietary modification with novel protein or hydrolyzed diets, may allow corticosteroid dose reduction in cats that require prolonged high-dose therapy. The decision to add an adjunct should be made early in cats with severe disease or those that relapse repeatedly during the taper, instead of after months of corticosteroid exposure.

Pretreatment Assessment and Staging

Before initiating corticosteroids, confirm the diagnosis of IBD through the standard sequence: fecal examination to exclude enteropathogens, serum cobalamin and folate measurement, abdominal ultrasonography, and intestinal biopsy when feasible. Cats with suspected IBD should also be screened for pancreatic disease, cholangitis, and chronic kidney disease, as these comorbidities alter drug choice and monitoring intensity. A complete blood count, serum biochemistry profile, and urinalysis establish baseline values for subsequent comparison. Blood pressure measurement and urine protein-to-creatinine ratio are advisable before starting therapy, since glucocorticoids can unmask or exacerbate hypertension and proteinuria in susceptible cats.

The decision to treat with corticosteroids presumes that dietary modification and, where indicated, antimicrobial trials have been addressed or are being pursued concurrently. Corticosteroids are not first-line therapy for every cat with chronic gastrointestinal signs. Cats with mild clinical signs and minimal histologic inflammation may respond to an elimination diet alone. The presence of moderate to severe clinical signs, weight loss, hypoalbuminemia, or marked inflammatory infiltrates on biopsy supports earlier introduction of glucocorticoids.

Induction Dosing and Administration

Prednisolone remains the standard induction agent for feline IBD. The oral formulation is preferred over prednisone because feline hepatic conversion of prednisone to prednisolone is less efficient than in dogs, although the clinical significance of this difference is debated. Current formulary references should be consulted for specific dose ranges, but induction typically uses anti-inflammatory to immunosuppressive doses administered once to twice daily. The dose is selected based on disease severity, body condition, and comorbidity burden. Cats with concurrent diabetes mellitus, heart disease, or poorly controlled hypertension require lower starting doses or alternative agents.

Oral administration is the default route. Compounded liquid formulations may improve owner compliance in cats that resist pilling, but compounding introduces variability in drug concentration and stability. The FDA Center for Veterinary Medicine provides guidance on compounding policy and extralabel drug use that practitioners should review when prescribing compounded products (FDA CVM animal drug information). Cats that vomit persistently or refuse oral medication may require short-term parenteral therapy, but this is uncommon in IBD management.

Budesonide is a locally acting corticosteroid with high first-pass hepatic metabolism, resulting in fewer systemic effects than prednisolone. It is a reasonable alternative for cats with mild to moderate disease, particularly those with comorbidities that increase the risk of systemic glucocorticoid adverse effects. However, the evidence base for budesonide in feline IBD is limited, and systemic absorption occurs in some cats. Clinical response and adverse effect monitoring should follow the same framework used for prednisolone.

Monitoring Parameters and Intervals

Therapeutic monitoring serves two distinct purposes: assessing disease control and detecting drug toxicity. These are not identical. A cat may have excellent clinical response while developing iatrogenic hyperadrenocorticism, or may have persistent intestinal inflammation despite normal fecal consistency. The latter scenario is well documented in feline lower airway disease, where resolution of clinical signs does not reliably indicate resolution of airway inflammation during high-dose glucocorticoid therapy (subclinical airway inflammation despite high-dose oral corticosteroid therapy in cats with lower airway disease). Whether the same dissociation occurs in feline IBD is not established, but the finding argues for objective monitoring beyond clinical signs where feasible.

Cats with inflammatory gastrointestinal disease exhibit increased care-soliciting and anxious behaviors compared with healthy cats, and corticosteroid treatment is associated with additional behavioral changes (cats with inflammatory gastrointestinal or dermatological disorders exhibit increased care-soliciting and anxious behaviors). Owners should be asked specifically about changes in grooming, sociability, and responses to novelty at each recheck. Behavioral deterioration may reflect glucocorticoid effects instead of disease progression, and this distinction changes management.

Tapering and Maintenance Strategy

Tapering begins once clinical signs are controlled, typically after 2 to 4 weeks at the induction dose. The taper should be gradual, reducing the dose by approximately 25% every 2 to 4 weeks while monitoring fecal consistency, appetite, and body weight. The goal is to identify the lowest effective maintenance dose, which may be every-other-day administration or a reduced daily dose. Some cats require long-term therapy, others can be weaned off corticosteroids entirely if dietary management alone maintains remission.

Rapid tapering risks relapse of clinical signs and does not meaningfully reduce the cumulative adverse effect burden. Prolonged therapy at supraphysiologic doses, by contrast, increases the risk of iatrogenic hyperadrenocorticism and its complications. The taper schedule should be documented in the medical record, with explicit criteria for slowing, pausing, or reversing the taper based on clinical response.

Adverse Effect Surveillance

Glucocorticoid adverse effects in cats include polyuria, polydipsia, polyphagia, weight gain, diabetes mellitus, hepatopathy, and immunosuppression. Cats are less prone to the classic iatrogenic hyperadrenocorticism phenotype seen in dogs, but the metabolic consequences are real. Ultrasonographic assessment of adrenal gland height does not reliably identify iatrogenic adrenal atrophy in cats, so imaging should not be used as a surrogate for adrenal function testing (iatrogenic adrenal atrophy following oral corticotherapy is not reliably identified ultrasonographically in cats). If hypoadrenocorticism is suspected after prolonged therapy, an ACTH stimulation test is the appropriate diagnostic.

Diabetes mellitus is a particular concern in cats receiving glucocorticoids. Serial blood glucose measurement, urine glucose dipstick testing at home, or periodic fructosamine measurement can detect emerging hyperglycemia. Cats that develop persistent hyperglycemia require dose reduction, alternative immunosuppressive therapy, or insulin therapy depending on severity and owner goals.

Documentation and Communication

The medical record should include the induction dose, the tapering schedule, body weight at each visit, fecal consistency scores, blood pressure measurements, and results of serial biochemistry panels. Owner observations of appetite, vomiting frequency, and behavior should be recorded systematically. Clear documentation supports dose adjustments, facilitates communication with referral colleagues, and provides a basis for revisiting the diagnosis if response is inadequate.

Owners should receive written instructions for medication administration, expected timelines for response, and specific criteria for contacting the practice. These include persistent vomiting, hematochezia, marked lethargy, or any sign of respiratory distress. The distinction between expected glucocorticoid effects such as increased thirst and concerning adverse effects should be explained explicitly.

Recognized Complications and Early Detection

The principal complications of corticosteroid therapy in feline IBD are iatrogenic hyperadrenocorticism, adrenal suppression, diabetes mellitus, and gastrointestinal adverse effects. Detection of adrenal atrophy is complicated by the limitations of ultrasonography. In a retrospective study of 308 cats, adrenal height decreased by only 21.4% (mean difference 0.8 mm) after more than one month of anti-inflammatory dosing, and no reliable adrenal height threshold distinguished treated from untreated cats. Ultrasonography therefore cannot be used to confirm or exclude iatrogenic adrenal suppression, and clinicians should rely on clinical signs and, when indicated, ACTH stimulation testing.

Diabetes mellitus is the most consequential metabolic complication. Cats receiving glucocorticoids should have blood glucose and urine glucose assessed at each recheck during induction and early maintenance. Polydipsia, polyuria, and weight loss despite adequate appetite warrant immediate glucose testing. Glucocorticoid-induced diabetes may resolve after dose reduction or discontinuation, but persistent hyperglycemia requires insulin therapy and long-term monitoring.

Gastrointestinal signs such as vomiting, diarrhea, or hematochezia can represent either progression of IBD or steroid-induced gastritis. Discriminating between these requires careful temporal correlation with dose changes. Cats that develop gastrointestinal signs shortly after dose escalation are more likely experiencing drug intolerance, whereas signs that emerge during tapering suggest disease relapse.

Common Clinical Errors and Corrective Actions

The most frequent error is treating clinical response as equivalent to histological remission. In a study of ten cats with lower airway disease receiving oral glucocorticoids at a mean dose of 1.8 mg/kg daily for at least three weeks, seven of ten cats had persistent inflammatory bronchoalveolar lavage cytology despite complete resolution of clinical signs. The same principle applies to intestinal inflammation: clinical improvement does not guarantee mucosal healing, and premature tapering based solely on owner-reported signs may permit subclinical inflammation to persist and progress.

A second common error is using prednisone instead of prednisolone. Cats absorb and convert oral prednisone to prednisolone inefficiently compared with dogs, and prednisolone is the preferred agent for feline therapy. Prescribers should verify the active ingredient on the prescription and pharmacy label.

A third error is tapering too rapidly after induction. Glucocorticoid dependence develops within weeks, and abrupt withdrawal can precipitate hypoadrenocorticism or severe disease flare. Tapering should follow a schedule that reduces the dose by no more than 25 to 50% every two to four weeks, with the final steps slowed further. Current formulary references should be consulted for specific tapering protocols.

A fourth error is failing to document baseline body weight, body condition score, and blood glucose before starting therapy. Without these values, subsequent monitoring for weight gain, muscle wasting, or hyperglycemia lacks a comparator.

Limitations of the Evidence and Areas of Disagreement

The evidence base for corticosteroid dosing in feline IBD is largely extrapolated from clinical experience and from studies in other feline inflammatory diseases. Prospective, randomised trials comparing prednisolone with budesonide or other alternatives in feline IBD are lacking. Expert opinion differs on the maximum acceptable maintenance dose, the optimal duration of induction, and whether budesonide offers meaningful safety advantages over prednisolone for long-term therapy.

Behavioral effects of corticosteroids in cats are increasingly recognized. Cats with inflammatory gastrointestinal disease exhibited more care-soliciting and anxious behaviors than healthy cats, and those treated with corticosteroids showed more anxious behaviors than untreated groups. Whether these behavioral changes reflect the disease process, the drug, or both remains uncertain, but owners should be counselled that personality changes may occur during therapy.

Referral, Consultation, and Reporting

Referral to a veterinary internal medicine specialist is warranted when a cat fails to respond to appropriate induction dosing within four to six weeks, when glucocorticoid requirements exceed immunosuppressive doses for more than three months, when diabetes mellitus develops and proves difficult to regulate, or when diagnostic uncertainty exists despite endoscopic biopsy. Specialist evaluation may include advanced imaging, repeat endoscopy, or alternative immunosuppressive protocols.

Clinical pathology laboratory consultation is appropriate when interpreting ACTH stimulation tests, when managing suspected hypoadrenocorticism during withdrawal, or when monitoring diabetic cats on concurrent glucocorticoid therapy.

Adverse drug event reporting to the FDA Center for Veterinary Medicine is encouraged for unexpected or severe reactions, particularly those not described in product labeling. Regulatory reporting obligations vary by jurisdiction, and practitioners should consult their local veterinary authority. The FDA maintains resources for reporting adverse events and accessing current drug information.

Frequently Asked Questions

How Should I Manage a Cat That Relapses During the Corticosteroid Taper?

A relapse during tapering usually indicates that the maintenance dose is too low or that the taper is proceeding too quickly. Return to the last dose that controlled clinical signs and maintain that dose for two to four weeks before attempting a slower taper. If relapse occurs at a dose that previously maintained remission, reassess the diagnosis. Repeat fecal testing, consider abdominal ultrasonography, and review dietary compliance. Recheck serum cobalamin and folate, as ongoing deficiency can mimic or exacerbate corticosteroid-refractory disease. If the cat requires sustained high-dose therapy to remain asymptomatic, revisit the possibility of alimentary lymphoma. Remember that resolution of clinical signs does not guarantee resolution of mucosal inflammation, as demonstrated in feline lower airway disease, so base decisions on objective parameters where available.

What Monitoring Is Feasible When Clients Have Limited Financial Resources?

Prioritize monitoring that changes management. Serial body weight, body condition score, and owner-reported fecal scoring cost nothing and detect most clinically relevant relapses. Measure serum biochemistry and urine specific gravity before starting therapy and again at four to eight weeks to screen for diabetes mellitus and proteinuria. Skip routine adrenal testing unless the cat develops signs of hypoadrenocorticism. Ultrasonographic adrenal measurement is unreliable for detecting iatrogenic atrophy in cats, so it should not be purchased as a screening test. If bloodwork is unaffordable, ask owners to monitor water intake, litter box use, and appetite weekly. A cat that develops polyuria, polydipsia, or polyphagia while on corticosteroids requires at minimum a urine glucose test, which is inexpensive and can be performed in-clinic.

How Do I Adjust Corticosteroid Dosing for a Cat With Concurrent Diabetes Mellitus?

Cats with diabetes mellitus and IBD present a genuine therapeutic conflict. Corticosteroids antagonize insulin action and can destabilize glycemic control. If corticosteroid therapy is unavoidable, use the lowest anti-inflammatory dose that achieves clinical benefit and prefer budesonide where available, as its first-pass hepatic metabolism may reduce systemic exposure, although this advantage is not guaranteed in every patient. Initiate or adjust insulin therapy concurrently and recheck blood glucose curves within five to seven days of any corticosteroid dose change. Consider alternative immunomodulation earlier in the treatment plan, including chlorambucil, to permit corticosteroid dose reduction. Communicate clearly with the owner that glycemic control may worsen transiently and that insulin requirements may increase. Monitor for diabetic ketoacidosis, particularly during induction, and hospitalize for intravenous fluid therapy if vomiting or anorexia develops.

What Records Should I Maintain for a Cat on Long-Term Corticosteroid Therapy?

Document the initial diagnostic staging, including histopathology if biopsy was performed, and the rationale for choosing a particular corticosteroid. Record the induction dose, the tapering schedule, and the date and reason for every dose adjustment. Maintain a problem list that tracks clinical signs, body weight, and adverse effects at each recheck. Note any concurrent medications, including topical or ophthalmic corticosteroids, which contribute to cumulative systemic exposure. Record client communications about expected adverse effects and monitoring plans. If the cat develops diabetes mellitus, iatrogenic hypoadrenocorticism, or other complications, document the temporal relationship to corticosteroid therapy. This record supports future clinical decisions and provides a defensible basis for prescribing decisions if questions arise. The FDA Center for Veterinary Medicine provides resources on adverse event reporting that may apply in your jurisdiction.

How Should I Explain Corticosteroid Risks to an Owner Who Is Reluctant to Start Therapy?

Acknowledge the owner's concern directly and distinguish between common manageable effects and rare serious complications. Explain that corticosteroids are not a cure but a tool to suppress inappropriate intestinal inflammation. Describe expected effects such as increased thirst, urination, and appetite, and reassure the owner that these usually resolve as the dose is tapered. Explain that diabetes mellitus can develop and that periodic blood and urine testing will detect it early. Note that cats with inflammatory disease may show increased care-soliciting and anxious behaviors, and that treatment can improve quality of life beyond gastrointestinal signs. Offer a concrete monitoring plan with scheduled rechecks so the owner knows what to expect. If the owner remains reluctant, discuss alternative immunosuppressive agents and their respective risk profiles.

Can I Use the Same Corticosteroid Protocol for a Cat With Suspected IBD When Biopsy Was Not Performed?

Yes, but with explicit caveats. Without histopathology, you cannot exclude alimentary lymphoma, which may respond transiently to corticosteroids but requires different long-term management. A therapeutic trial of corticosteroids is reasonable when clinical signs, physical examination, and ultrasonographic findings support inflammatory disease and when the owner declines or cannot afford biopsy. Establish response criteria before starting therapy, including expected improvement in vomiting frequency, fecal consistency, appetite, and weight gain within two to four weeks. If the cat fails to respond adequately, biopsy becomes mandatory instead of optional. Document the presumptive diagnosis clearly in the medical record and revisit the diagnostic plan at every recheck. The MSD Veterinary Manual provides guidance on the diagnostic approach to chronic enteropathy in cats.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Subclinical airway inflammation despite high-dose oral corticosteroid therapy in cats with lower airway disease.. 2011.
• AL-2512, a novel corticosteroid: preclinical assessment of anti-inflammatory and ocular hypertensive effects.. 2003.
• Cats with inflammatory gastrointestinal or dermatological disorders exhibit increased care-soliciting and anxious behaviors.. 2025.
• Iatrogenic adrenal atrophy following oral corticotherapy is not reliably identified ultrasonographically in cats.. 2023.
• Serum protein alterations characterize feline chronic gingivostomatitis: a case-control study of electrophoresis, immunoglobulin, and cytokine profiles.. 2026.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Corticosteroid Therapy in Canine Atopic Dermatitis: Dosing and Monitoring
• Corticosteroid Therapy in Feline Diseases: Special Considerations
• Corticosteroid Therapy in Canine Inflammatory Diseases: Balancing Efficacy and Safety
• Corticosteroid Therapy in Equine Joint Disease: Intra-articular vs Systemic Use
• Corticosteroid Injections in Dogs: Indications, Risks, and Monitoring

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.